News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
819,421 Results
Type
Article (84938)
Company Profile (620)
Press Release (733863)
Section
Business (231079)
Career Advice (4067)
Deals (39605)
Drug Delivery (102)
Drug Development (90207)
Employer Resources (192)
FDA (17770)
Job Trends (17219)
News (393402)
Policy (39537)
Tag
Academia (2967)
Africa (1259)
Alabama (32)
Allergies (41)
Alliances (56204)
Alzheimer's disease (1191)
Antibody-drug conjugate (ADC) (58)
Approvals (17717)
Arizona (187)
Artificial intelligence (55)
Asia (48733)
Australia (8574)
Bankruptcy (392)
Best Places to Work (12144)
Biosimilars (62)
C2C Services and Suppliers (95129)
California (769)
Canada (614)
Cancer (199)
Career advice (3482)
CAR-T (44)
Cell therapy (82)
China (42)
Clinical research (69766)
Collaboration (59)
COVID-19 (2714)
Cystic fibrosis (73)
Diabetes (34)
Diagnostics (6397)
Diversity, equity & inclusion (48)
Drug pricing (58)
Earnings (92534)
Employer resources (160)
Europe (111399)
Events (123996)
FDA (17805)
Florida (94)
Funding (41)
Gene therapy (62)
GLP-1 (556)
Government (4973)
Healthcare (20533)
Hotbed/Location (534692)
Idaho (62)
Illinois (236)
Indiana (109)
Infectious disease (2726)
Inflammatory bowel disease (94)
Interviews (804)
IPO (17401)
Job creations (5170)
Job search strategy (2846)
Kansas (96)
Layoffs (442)
Legal (9989)
Liver cancer (57)
Lung cancer (46)
Maine (52)
Management (59)
Manufacturing (56)
Maryland (262)
Massachusetts (440)
Medical device (14137)
Medtech (14140)
Mergers & acquisitions (21857)
Metabolic disorders (180)
Neuroscience (1280)
New Jersey (45)
New York (66)
NextGen Class of 2024 (7616)
Non-profit (5029)
North Carolina (173)
Obesity (114)
Opinion (221)
Parkinson's disease (32)
Patents (36)
Peanut (37)
Pennsylvania (37)
People (63361)
Phase I (21440)
Phase II (30293)
Phase III (22897)
Podcasts (64)
Policy (39)
Postmarket research (3529)
Preclinical (9722)
Rare diseases (92)
Real estate (7357)
Recruiting (72)
Regulatory (25372)
Reports (42)
Research institute (2622)
Resumes & cover letters (642)
South America (1641)
Startups (4259)
Texas (79)
United States (2964)
Vaccines (495)
Washington State (110)
Weight loss (119)
Date
Today (51)
Last 7 days (377)
Last 30 days (1646)
Last 365 days (40796)
2024 (23078)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51342)
2018 (39126)
2017 (37194)
2016 (38330)
2015 (44435)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
819,421 Results for "belite bio llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Belite Bio, Inc announces that its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan for the treatment of STGD1.
June 12, 2024
·
5 min read
Biotech Beach
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.
May 1, 2024
·
5 min read
Business
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
Belite Bio, Inc announced its financial results for the first quarter ended March 31, 2024 and provided a general business update.
May 13, 2024
·
10 min read
Biotech Beach
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
Belite Bio, Inc. today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024.
May 14, 2024
·
1 min read
Biotech Beach
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
Belite Bio, Inc. (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced additional findings from the 24-month Phase 2 study of Tinlarebant in adolescent Stargardt disease (STGD1) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
May 6, 2024
·
8 min read
Business
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
Belite Bio, Inc today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.
May 8, 2024
·
1 min read
Biotech Beach
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
Belite Bio, Inc. today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024.
March 4, 2024
·
1 min read
News
Belite Bio to Present at the JonesHealthcare Seaside Summit
July 8, 2024
·
1 min read
Biotech Beach
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Belite Bio, Inc today announces its submission to the Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a clinical trial of Tinlarebant in adolescent STGD1 in Japan (“DRAGON II”).
March 22, 2024
·
5 min read
Biotech Beach
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference being held in New York, NY, on May 20, 2024. The Company will host a fireside chat at 3:30 pm ET. A web
May 13, 2024
·
1 min read
1 of 81,943
Next
